| Previous close | 3.0000 |
| Open | 3.0000 |
| Bid | 0.4700 |
| Ask | 3.6000 |
| Strike | 280.00 |
| Expiry date | 2025-01-17 |
| Day's range | 3.0000 - 3.0000 |
| Contract range | N/A |
| Volume | |
| Open interest | 127 |
Yahoo Finance3 stocks with the biggest gains took April's biggest losses
The stock market's very rough April saw some of the biggest gainers of the first three months take some of the biggest dings to their market caps. And at the same time, some of the sectors that struggled in Q1 saw a similar reversal of fortune in April.
- Reuters
UPDATE 3-Novo Nordisk raises outlook fuelled by obesity drug demand
Novo Nordisk raised its 2024 outlook on Thursday and delivered better-than-expected quarterly profits as the Danish drugmaker races to boost output of its hugely popular weight-loss drug Wegovy and fend off competition from rival Eli Lilly. The company has quadrupled its U.S. supply of starter doses Wegovy since December, Senior Vice President Negelle Morris told Reuters this week. At least 20,000 new U.S. patients are starting on the weekly injection each week, reflecting the company's efforts to ramp up output, she said.
ReutersNovo Nordisk raises outlook fuelled by obesity drug demand
LONDON (Reuters) -Novo Nordisk raised its 2024 outlook on Thursday and delivered better-than-expected quarterly profits as the Danish drugmaker races to boost output of its hugely popular weight-loss drug Wegovy and fend off competition from rival Eli Lilly. The company has quadrupled its U.S. supply of starter doses Wegovy since December, Senior Vice President Negelle Morris told Reuters this week. At least 20,000 new U.S. patients are starting on the weekly injection each week, reflecting the company's efforts to ramp up output, she said.
